These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 6318787)

  • 1. Ranitidine disposition in patients with renal impairment.
    Meffin PJ; Grgurinovich N; Brooks PM; Miners JO; Cochran M; Stranks G
    Br J Clin Pharmacol; 1983 Dec; 16(6):731-4. PubMed ID: 6318787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of ranitidine in patients with chronic renal failure.
    McFadyen ML; Folb PI; Miller R; Keeton GR; Marks IN
    Eur J Clin Pharmacol; 1983; 25(3):347-51. PubMed ID: 6313378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ranitidine kinetics in chronic renal impairment.
    Zech PY; Chau NP; Pozet N; Labeeuw M; Hadj-Aissa A
    Clin Pharmacol Ther; 1983 Nov; 34(5):667-72. PubMed ID: 6313275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dosage regimen of ranitidine in patients with renal impairment.
    Ebihara A; Ohashi K; Ikeda T; Yuhara M; Tagawa H; Yamakado M; Asano Y; Tabei K; Nakazawa K; Kondo K
    Int J Clin Pharmacol Res; 1989; 9(1):1-7. PubMed ID: 2707920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of ranitidine in patients with renal failure.
    Garg DC; Baltodano N; Jallad NS; Perez G; Oster JR; Eshelman FN; Weidler DJ
    J Clin Pharmacol; 1986 Apr; 26(4):286-91. PubMed ID: 3700684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and pharmacodynamics of ranitidine in renal impairment.
    Koch KM; Liu M; Davis IM; Shaw S; Yin Y
    Eur J Clin Pharmacol; 1997; 52(3):229-34. PubMed ID: 9218931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High dose of antacid (Mylanta II) reduces bioavailability of ranitidine.
    Mihaly GW; Marino AT; Webster LK; Jones DB; Louis WJ; Smallwood RA
    Br Med J (Clin Res Ed); 1982 Oct; 285(6347):998-9. PubMed ID: 6289961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of renal function on the pharmacokinetics of ranitidine.
    Dixon JS; Borg-Costanzi JM; Langley SJ; Lacey LF; Toon S
    Eur J Clin Pharmacol; 1994; 46(2):167-71. PubMed ID: 8039538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ranitidine disposition and systemic availability in hepatic cirrhosis.
    Smith IL; Ziemniak JA; Bernhard H; Eshelman FN; Martin LE; Schentag JJ
    Clin Pharmacol Ther; 1984 Apr; 35(4):487-94. PubMed ID: 6323087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical pharmacokinetics of ranitidine.
    Roberts CJ
    Clin Pharmacokinet; 1984; 9(3):211-21. PubMed ID: 6329583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ranitidine disposition in severe hepatic cirrhosis.
    Gonzalez-Martin G; Paulos C; Veloso B; Chesta J; Novoa X; Arancibia A
    Int J Clin Pharmacol Ther Toxicol; 1987 Mar; 25(3):139-42. PubMed ID: 3557740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and bioavailability of ranitidine in normal subjects and cirrhotic patients.
    Morichau-Beauchant M; Houin G; Mavier P; Alexandre C; Dhumeaux D
    Dig Dis Sci; 1986 Feb; 31(2):113-8. PubMed ID: 3943439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of the H2- receptor antagonist ranitidine in man.
    McNeil JJ; Mihaly GW; Anderson A; Marshall AW; Smallwood RA; Louis WJ
    Br J Clin Pharmacol; 1981 Sep; 12(3):411-5. PubMed ID: 6117305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ranitidine: single dose pharmacokinetics and absolute bioavailability in man.
    van Hecken AM; Tjandramaga TB; Mullie A; Verbesselt R; de Schepper PJ
    Br J Clin Pharmacol; 1982 Aug; 14(2):195-200. PubMed ID: 6125204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of ranitidine on the disposition of lignocaine.
    Robson RA; Wing LM; Miners JO; Lillywhite KJ; Birkett DJ
    Br J Clin Pharmacol; 1985 Aug; 20(2):170-3. PubMed ID: 4041336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ranitidine has no influence on tubular creatinine secretion.
    van den Berg JG; Koopman MG; Arisz L
    Nephron; 1996; 74(4):705-8. PubMed ID: 8956305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of renal impairment on disposition of pentopril and its active metabolite.
    Rakhit A; Radensky P; Szerlip HM; Kochak GM; Audet PR; Hurley ME; Feldman GM
    Clin Pharmacol Ther; 1988 Jul; 44(1):39-48. PubMed ID: 3391004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ranitidine bioavailability and kinetics in normal male subjects.
    Garg DC; Weidler DJ; Eshelman FN
    Clin Pharmacol Ther; 1983 Apr; 33(4):445-52. PubMed ID: 6299642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ranitidine bioavailability and disposition kinetics in patients undergoing chronic hemodialysis.
    Comstock TJ; Sica DA; Harford A; Eshelman F
    Nephron; 1989; 52(1):15-9. PubMed ID: 2710266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of renal function impairment of iproplatin pharmacokinetics and relation to toxicity.
    Pendyala L; Madajewicz S; Creaven PJ
    Cancer Res; 1985 Nov; 45(11 Pt 2):5936-8. PubMed ID: 4053065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.